• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Comment on biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis.

作者信息

Walker Lucy J, Newton Julia, Jones David E J, Bassendine Margaret F

出版信息

Hepatology. 2009 Jan;49(1):337-8; author reply 338. doi: 10.1002/hep.22670.

DOI:10.1002/hep.22670
PMID:19035342
Abstract
摘要

相似文献

1
Comment on biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis.原发性胆汁性肝硬化对熊去氧胆酸的生化反应及长期预后的评论
Hepatology. 2009 Jan;49(1):337-8; author reply 338. doi: 10.1002/hep.22670.
2
Combination therapy of bezafibrate and ursodeoxycholic acid in primary biliary cirrhosis: a preliminary study.苯扎贝特与熊去氧胆酸联合治疗原发性胆汁性肝硬化的初步研究。
Am J Gastroenterol. 2000 Jan;95(1):326-7. doi: 10.1111/j.1572-0241.2000.01667.x.
3
Bezafibrate treatment of primary biliary cirrhosis following incomplete response to ursodeoxycholic acid.熊去氧胆酸治疗原发性胆汁性肝硬化应答不完全后应用苯扎贝特治疗。
J Clin Gastroenterol. 2010 May-Jun;44(5):371-3. doi: 10.1097/MCG.0b013e3181c115b3.
4
Long-term ursodeoxycholic acid therapy for primary biliary cirrhosis: a follow-up to 12 years.熊去氧胆酸长期治疗原发性胆汁性肝硬化：长达12年的随访
Aliment Pharmacol Ther. 2005 Feb 1;21(3):217-26. doi: 10.1111/j.1365-2036.2005.02318.x.
5
Ursodeoxycholic acid and long-term survival in primary biliary cirrhosis.熊去氧胆酸与原发性胆汁性肝硬化的长期生存
Am J Gastroenterol. 2004 Feb;99(2):269-70.
6
Fenofibrate treatment in patients with primary biliary cirrhosis.非诺贝特治疗原发性胆汁性肝硬化患者。
Am J Gastroenterol. 2002 Aug;97(8):2147-9. doi: 10.1111/j.1572-0241.2002.05944.x.
7
Long-term response of primary biliary cirrhosis (stage I) to therapy with ursodeoxycholic acid.原发性胆汁性肝硬化（I期）对熊去氧胆酸治疗的长期反应。
Hepatogastroenterology. 2005 May-Jun;52(63):753-6.
8
Methotrexate therapy for the symptomatic treatment of primary biliary cirrhosis patients, who are biochemical incomplete responders to ursodeoxycholic acid therapy.甲氨蝶呤用于对熊去氧胆酸治疗生化反应不完全的原发性胆汁性肝硬化患者进行症状性治疗。
Aliment Pharmacol Ther. 2006 Sep 1;24(5):813-20. doi: 10.1111/j.1365-2036.2006.03048.x.
9
Bezafibrate treatment: a new medical approach for PBC patients?苯扎贝特治疗：原发性胆汁性胆管炎患者的一种新的医学治疗方法？
J Gastroenterol. 2003;38(6):573-8. doi: 10.1007/s00535-002-1102-7.
10
Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid.对熊去氧胆酸有生化反应的原发性胆汁性肝硬化患者预后改善。
Gastroenterology. 2009 Apr;136(4):1281-7. doi: 10.1053/j.gastro.2009.01.003. Epub 2009 Jan 14.

引用本文的文献

1
Efficacy and safety of fenofibrate add-on therapy in patients with primary biliary cholangitis refractory to ursodeoxycholic acid: A retrospective study and updated meta-analysis.非诺贝特联合治疗对熊去氧胆酸难治的原发性胆汁性胆管炎患者的疗效和安全性：一项回顾性研究及更新的荟萃分析
Front Pharmacol. 2022 Aug 30;13:948362. doi: 10.3389/fphar.2022.948362. eCollection 2022.
2
Statins, Fibrates, and Other Peroxisome Proliferator-Activated Receptor Agonists for the Treatment of Cholestatic Liver Diseases.他汀类药物、贝特类药物及其他过氧化物酶体增殖物激活受体激动剂用于治疗胆汁淤积性肝病
Gastroenterol Hepatol (N Y). 2020 Jan;16(1):31-38.
3
Treatment of primary biliary cirrhosis: Is there more to offer than ursodeoxycholic acid?
原发性胆汁性肝硬化的治疗：除了熊去氧胆酸还有更多可提供的治疗方法吗？
Clin Liver Dis (Hoboken). 2014 Mar 5;3(2):29-33. doi: 10.1002/cld.311. eCollection 2014 Feb.
4
Update on New Drugs and Those in Development for the Treatment of Primary Biliary Cholangitis.原发性胆汁性胆管炎治疗新药及研发中药物的最新进展
Gastroenterol Hepatol (N Y). 2018 Mar;14(3):154-163.
5
Effects of Bezafibrate on Outcome and Pruritus in Primary Biliary Cholangitis With Suboptimal Ursodeoxycholic Acid Response.苯扎贝特对熊去氧胆酸应答不佳的原发性胆汁性胆管炎结局和瘙痒的影响。
Am J Gastroenterol. 2018 Jan;113(1):49-55. doi: 10.1038/ajg.2017.287. Epub 2017 Oct 10.
6
Inhibition of JNK signalling mediates PPARα-dependent protection against intrahepatic cholestasis by fenofibrate.抑制JNK信号传导介导非诺贝特对肝内胆汁淤积的PPARα依赖性保护作用。
Br J Pharmacol. 2017 Sep;174(18):3000-3017. doi: 10.1111/bph.13928. Epub 2017 Aug 10.
7
Clinical significance of changes in the Th17/Treg ratio in autoimmune liver disease.自身免疫性肝病中Th17/Treg比值变化的临床意义
World J Gastroenterol. 2017 Jun 7;23(21):3832-3838. doi: 10.3748/wjg.v23.i21.3832.
8
Long-Term Fenofibrate Treatment in Primary Biliary Cholangitis Improves Biochemistry but Not the UK-PBC Risk Score.原发性胆汁性胆管炎的长期非诺贝特治疗可改善生化指标，但不能改善英国原发性胆汁性胆管炎风险评分。
Dig Dis Sci. 2016 Oct;61(10):3037-3044. doi: 10.1007/s10620-016-4250-y. Epub 2016 Jul 19.
9
Proposed therapies in primary biliary cholangitis.原发性胆汁性胆管炎的推荐疗法。
Expert Rev Gastroenterol Hepatol. 2016;10(3):371-382. doi: 10.1586/17474124.2016.1121810. Epub 2016 Jan 6.
10
Combination therapy of fenofibrate and ursodeoxycholic acid in patients with primary biliary cirrhosis who respond incompletely to UDCA monotherapy: a meta-analysis.非诺贝特与熊去氧胆酸联合治疗对熊去氧胆酸单药治疗反应不完全的原发性胆汁性肝硬化患者：一项荟萃分析。
Drug Des Devel Ther. 2015 May 25;9:2757-66. doi: 10.2147/DDDT.S79837. eCollection 2015.